Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
90.01
+1.63 (1.84%)
Apr 18, 2024, 2:01 PM EDT - Market open
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 83.86, with a low estimate of 43 and a high estimate of 115. The average target predicts a decrease of -6.83% from the current stock price of 90.01.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BPMC stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 14 | 13 | 14 | 15 | 15 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $114 | Buy | Reiterates | $114 | +26.65% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $97 | Strong Buy | Reiterates | $97 | +7.77% | Feb 26, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $114 | Buy | Reiterates | $114 | +26.65% | Feb 16, 2024 |
| Citigroup | Citigroup | Strong Sell Maintains $54 → $65 | Strong Sell | Maintains | $54 → $65 | -27.79% | Feb 16, 2024 |
| Barclays | Barclays | Hold Maintains $58 → $70 | Hold | Maintains | $58 → $70 | -22.23% | Feb 13, 2024 |
Financial Forecast
Revenue This Year
400.57M
from 249.38M
Increased by 60.63%
Revenue Next Year
607.95M
from 400.57M
Increased by 51.77%
EPS This Year
-5.66
from -8.37
EPS Next Year
-2.83
from -5.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 471.5M | 775.9M | 1.1B | 1.3B | 1.2B |
| Avg | 400.6M | 608.0M | 846.0M | 969.0M | 1.0B |
| Low | 364.6M | 471.6M | 600.1M | 670.7M | 799.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 89.0% | 93.7% | 77.0% | 55.9% | 27.5% |
| Avg | 60.6% | 51.8% | 39.1% | 14.5% | 7.3% |
| Low | 46.2% | 17.7% | -1.3% | -20.7% | -17.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.59 | -0.28 | 4.54 | 8.36 | 4.56 |
| Avg | -5.66 | -2.83 | 0.57 | 2.31 | 2.57 |
| Low | -6.15 | -6.33 | -2.41 | -2.48 | -0.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,369.0% | 97.6% |
| Avg | - | - | - | 305.4% | 11.2% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.